Inspire Medical Systems (INSP) Expected to Post Quarterly Sales of $14.00 Million

Equities analysts expect Inspire Medical Systems (NASDAQ:INSP) to post sales of $14.00 million for the current quarter, according to Zacks. Three analysts have issued estimates for Inspire Medical Systems’ earnings, with the lowest sales estimate coming in at $13.90 million and the highest estimate coming in at $14.10 million. The company is expected to issue its next quarterly earnings results on Tuesday, February 5th.

According to Zacks, analysts expect that Inspire Medical Systems will report full-year sales of $48.00 million for the current year, with estimates ranging from $47.90 million to $48.10 million. For the next fiscal year, analysts forecast that the firm will post sales of $63.33 million, with estimates ranging from $61.20 million to $64.50 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Inspire Medical Systems.

Inspire Medical Systems (NASDAQ:INSP) last announced its quarterly earnings results on Tuesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.13. The business had revenue of $13.10 million during the quarter, compared to analysts’ expectations of $12.86 million. During the same period last year, the company earned ($3.42) EPS. The firm’s revenue for the quarter was up 79.9% on a year-over-year basis.

INSP has been the topic of several recent research reports. Zacks Investment Research downgraded shares of Inspire Medical Systems from a “hold” rating to a “sell” rating in a report on Wednesday, November 21st. Leerink Swann initiated coverage on shares of Inspire Medical Systems in a report on Monday, October 29th. They issued an “outperform” rating and a $57.00 price target on the stock. Finally, Berenberg Bank initiated coverage on shares of Inspire Medical Systems in a report on Wednesday, November 28th. They issued a “sell” rating and a $31.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.63.

In related news, CEO Timothy P. Herbert sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $39.89, for a total transaction of $598,350.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Randy Ban sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $40.37, for a total transaction of $403,700.00. The disclosure for this sale can be found here.

Several institutional investors and hedge funds have recently made changes to their positions in INSP. MetLife Investment Advisors LLC purchased a new position in shares of Inspire Medical Systems during the third quarter valued at approximately $199,000. Valeo Financial Advisors LLC acquired a new position in Inspire Medical Systems during the second quarter worth approximately $229,000. Rhumbline Advisers acquired a new position in Inspire Medical Systems during the second quarter worth approximately $243,000. Bank of America Corp DE acquired a new position in Inspire Medical Systems during the second quarter worth approximately $306,000. Finally, Dupont Capital Management Corp acquired a new position in Inspire Medical Systems during the third quarter worth approximately $314,000.

Shares of NASDAQ INSP opened at $45.94 on Monday. Inspire Medical Systems has a 12-month low of $22.50 and a 12-month high of $57.87.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

See Also: Rule of 72

Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inspire Medical Systems (NASDAQ:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit